PKNGF ProStrakan Group Plc featured news, full reports, and detailed charts
ProStrakan Group Plc (PKNGF/PKNGF.PK) Wrap Up:
ProStrakan Group plc develops and commercializes prescription medicines. The company offers its products for women's health, the ageing male, and bone disease therapeutic areas. It offers Adcal for osteoporosis and the correction of calcium deficiency; Adcal D3 for therapeutic supplementation of malnutrition; Alfaprost to treat moderate benign prostatic hypertrophy; AmsaLyo for lymphoblastic and myeloblastic acute leukemia; and Belustine to treat brain tumors, small cell and epidermoid lung cancer, melanomas, Hodgkin's and non-Hodgkin's lymphomas, and myelomas. ProStrakan Group also provides Calci APS to correct calcium and vitamin D deficiency; Ciprofloxacino for bacterial infections of the urinary tract; Dehidrobenzoperidol, Dehydrobenzperidol, Dridol, and Droleptan indications for droperidol; Desuric to treat severe gout; Devogel for the relief of vaginal dryness; Fluconazol Elfar to treat candidiasis; Flutamida Elfar for the palliative treatment of prostatic carcinoma; Hexastat for the second line treatment of ovarian cancer and small cell lung cancer; and Ketensin to treat acute hypertensive episodes. In addition, it offers Meto APS to treat hypertension; Perfane indicated for the short term treatment of acute congestive cardiac failure; Piprol to treat bacterial urinary tract infections; Rectogesic indicated for the relief of chronic anal fissure pain; Simva APS to treat hyper-cholesterolaemia; Sinovial to treat knee arthrosis; and Sufil 500mg to treat helmintiasis. Further, the company provides Tabphyn to treat benign prostatic hyperplasia; Tamoxifeno Elfar for breast cancer; Tebetane Compuesto to treat mild benign prostatic hypertrophy; Tostrex for use in hypogonadal men; and Urinorm to treat severe gout in patients. It sells its products in through its own sales force, bespoke sales teams, and licensing and distribution agreements in Europe and internationally. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom.ProStrakan Group Plc (PKNGF:Pink OTC Markets Inc)
Snapshot of ProStrakan Group Plc (PKNGF)
|
OPEN
--
|
PREVIOUS CLOSE
$1.81
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
09/2/09 - $2.60
|
52 WEEK LOW
02/18/09 - $1.10
|
|
|
MARKET CAP
364.3M
|
AVERAGE VOLUME 3 mo
0.0
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
201.3M
|
|
|
PKNGF Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
PKNGF Top Compensated Officers
Executives, Board Directors
Key developments for ProStrakan Group Plc (PKNGF)
ProStrakan Group plc announced that the US Food and Drug Administration has confirmed acceptance for review of ProStrakan's refiling of its New Drug Application ('NDA') for Cellegesic™ (nitroglycerin) 0.4% Ointment for the treatment of moderate to severe pain associated with chronic anal fissures. This refiling was made in response to the Action Letter issued by the FDA for Cellegesic on 7th July 2006. Nitroglycerin-containing compounds are already recommended by a number of European and US clinical bodies for the pharmacological treatment of moderate to severe pain associated with chronic anal fissures, particularly as first line therapy, before resorting to surgery. Rectal use of nitroglycerin-containing compounds is well established in the US. Currently, these compounds are prepared at pharmacy outlets and there is therefore no assurance to the quality or strength of drug that the patient receives. Also, the safety and efficacy of these products have not been approved by the FDA. Subject to approval by the FDA, Cellegesic will be the first nitroglycerin product licensed in the US to address this unmet need.
Orexo AB confirms that its partner, ProStrakan Group plc, announced that the New Drug Application (NDA) filing for Abstral has been accepted for review by the US Food and Drug Administration (FDA). Abstral is a new, rapidly disintegrating, sublingual formulation of fentanyl, a long-established opioid used for the management of episodes of breakthrough pain experienced by cancer patients who are already receiving opioid analgesics for their chronic pain. Subject to successful completion of the US approval process, ProStrakan plans to launch Abstral in the US in the second half of 2010.
ProStrakan Group plc announced that Allan Watson has joined the Company as Chief Financial Officer (CFO) and was appointed to the Group's Board of Directors. Allan (42) joins ProStrakan from medical technology company, Optos plc, where he had been CFO since 2003.
PKNGF Competitors
| Company | Last | Change |
| Antisoma | 31.25 GBX | -0.25 |
| Ascent Pharmahealth Ltd | A$0.20 AUD | 0.00 |
| GW Pharmaceuticals | 93.00 GBX | -1.00 |
| Walter Investment Management Corp | $12.50 USD | -0.25 |
| Oxford Biomedica | 13.25 GBX | 0.00 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | PKNGF | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 347.3x |
|
| Price/Book | 730.3x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 346.3x |
|
|
PKNGF |
||
PKNGF transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||